|Articles|May 20, 2021
Process Purification Development of Retrovirus-like Particle
Author(s)Bio-Rad Laboratories
Read a case study about resin screening, process development, and scale-up purification of a retrovirus-like particle which was scalable, fast, and low-cost during the clinical-grade manufacture of retrovirus vectors.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Neurimmune and AstraZeneca Expand Efforts to Accelerate Fibril-Depleting Therapies
2
New Draft Guidance Highlights FDA Push Toward Human-Relevant Safety Models
3
Implementing Automation and Flexible Design for Allogeneic Manufacturing
4
Regulatory Uncertainty Surfaces as FDA Blames COVID Vaccines for 10 Child Deaths
5
